Our research provides two important insights: (1) Nanocarriers can enhance targeting and immunogenicity by optimizing the immune feedback loop (STING → IFN → PD-L1 upregulation), converting an anti-tumor mechanism into a therapeutic advantage. The gene discussed is IFNA1; the disease is neoplasm.